Cleared Traditional

K905257 - OPUS CMV TEST SYSTEM

K905257 is the FDA 510(k) clearance for OPUS CMV TEST SYSTEM by Pb Diagnostic Systems, Inc.. It is a Class 2 Microbiology device (product code LIN) cleared through the Traditional 510(k) pathway after a 147-day FDA review.

K905257 · Pb Diagnostic Systems, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1991
Decision
147d
Days
Class 2
Risk

K905257 is an FDA 510(k) clearance for the OPUS CMV TEST SYSTEM. Classified as Antisera, Conjugated Fluorescent, Cytomegalovirus (product code LIN), Class II - Special Controls.

Submitted by Pb Diagnostic Systems, Inc. (Westwood, US). The FDA issued a Cleared decision on April 17, 1991 after a review of 147 days - within the typical 510(k) review window.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3175 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Pb Diagnostic Systems, Inc. devices

Submission Details

510(k) Number K905257 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 21, 1990
Decision Date April 17, 1991
Days to Decision 147 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
45d slower than avg
Panel avg: 102d · This submission: 147d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LIN Antisera, Conjugated Fluorescent, Cytomegalovirus
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3175
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - LIN Antisera, Conjugated Fluorescent, Cytomegalovirus

All 11
Devices cleared under the same product code (LIN) and FDA review panel - the closest regulatory comparables to K905257.
PATHODX CYTOMEGALOVIRUS
K934798 · Diagnostic Products Corp. · Mar 1994
CMV-VUE(TM) CMV ANTIGEN DETECTION KIT
K921616 · Incstar Corp. · Aug 1992
CMV-EA MAB TEST
K912592 · Gull Laboratories, Inc. · Dec 1991
BARTELS CYTOMEGALOVIRUS IMMED. EARLY ANTIGEN
K904036 · Baxter Healthcare Corp · Oct 1990
CYTOMEGALOVIRUS FLUORESCENT MONOCLONAL ANTIBODY
K894002 · Baxter Healthcare Corp · Aug 1989
CMV IGG ANTIBODY TEST (INDIRECT ENZYME TEST)
K893467 · Immuno Concepts, Inc. · Jul 1989